AGENTIX and RTI International Announce Worldwide Exclusive License and Services Agreement
New York, New York--(Newsfile Corp. - December 21, 2021) - AGENTIX Corporation (OTC Pink: AGTX), a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics for the treatment of metabolic diseases, announced today it has entered into an amendment to a Patent and Know-How License Agreement between the parties, dated October 22, 2021, a worldwide exclusive license and services agreement with Research Triangle Institute, dba RTI International ("RTI"), a...
2021-12-21 5:00 AM EST
AGENTIX Corporation and the National Health Research Institutions Announce Worldwide Exclusive License Agreements
New York, New York--(Newsfile Corp. - September 8, 2021) - AGENTIX Corp. (OTC Pink: AGTX), a pharmaceutical company focused on developing innovative therapeutic treatments targeting the endocannabinoid system (ECS) for the treatment of metabolic diseases, announced today it had entered into a worldwide exclusive license agreement and technology transfer agreement with the National Health Research Institutes ("NHRI") of Taiwan ROC, a nonprofit research institute, concerning the development and...
2021-09-08 8:00 AM EDT